{
    "clinical_study": {
        "@rank": "99350", 
        "brief_summary": {
            "textblock": "To study the toxicity and efficacy of IV mitoxantrone hydrochloride (Novantrone) in\n      AIDS-related Kaposi's sarcoma."
        }, 
        "brief_title": "Phase II Study of Intravenous Novantrone(R) in the Treatment of AIDS Related Kaposi's Sarcoma", 
        "condition": [
            "Sarcoma, Kaposi", 
            "HIV Infections"
        ], 
        "condition_browse": {
            "mesh_term": [
                "HIV Infections", 
                "Acquired Immunodeficiency Syndrome", 
                "Sarcoma, Kaposi", 
                "AIDS-Related Opportunistic Infections", 
                "Sarcoma"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria\n\n        Patients must have the following:\n\n          -  Biopsy proven Kaposi's sarcoma in advanced stages.\n\n          -  Positive HIV antibody, HIV culture or antigen capture or T4 cells < 500 in a patient\n             with AIDS risk factor.\n\n          -  Informed consent and availability for follow-up.\n\n        Exclusion Criteria\n\n        Co-existing Condition:\n\n        Patients with the following conditions or symptoms are excluded:\n\n          -  Uncontrolled opportunistic infection.\n\n          -  Any medical, surgical or psychiatric condition which would constitute a\n             contraindication to the use of mitoxantrone.\n\n        Concurrent Medication:\n\n        Excluded:\n\n          -  Zidovudine (AZT).\n\n        Patients with the following are excluded:\n\n          -  Uncontrolled opportunistic infection.\n\n          -  Unable to give informed consent.\n\n          -  Any medical, surgical or psychiatric condition which would constitute a\n             contraindication to the use of mitoxantrone.\n\n        Prior Medication:\n\n        Excluded:\n\n          -  More than one form of chemotherapy regimen.\n\n          -  Doxorubicin therapy > 300 mg/m2.\n\n        Prior Treatment:\n\n        Excluded:\n\n          -  Previous therapy consisting of more than one modality of therapy (e.g., chemotherapy\n             plus radiotherapy or more than one form of chemotherapy regimen.)"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "firstreceived_date": "November 2, 1999", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00002259", 
            "org_study_id": "055B", 
            "secondary_id": "3-102"
        }, 
        "intervention": {
            "intervention_name": "Mitoxantrone hydrochloride", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": "Mitoxantrone"
        }, 
        "keyword": [
            "Mitoxantrone", 
            "Acquired Immunodeficiency Syndrome"
        ], 
        "lastchanged_date": "June 23, 2005", 
        "location": {
            "facility": {
                "address": {
                    "city": "New York", 
                    "country": "United States", 
                    "state": "New York", 
                    "zip": "10019"
                }, 
                "name": "Saint Luke's - Roosevelt Hosp Ctr"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "official_title": "Phase II Study of Intravenous Novantrone(R) in the Treatment of AIDS Related Kaposi's Sarcoma", 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration"
        }, 
        "phase": "Phase 2", 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00002259"
        }, 
        "source": "NIH AIDS Clinical Trials Information Service", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Lederle Laboratories", 
                "agency_class": "Industry"
            }
        }, 
        "study_design": "Endpoint Classification: Efficacy Study, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "August 1991"
    }, 
    "geocoordinates": {
        "Saint Luke's - Roosevelt Hosp Ctr": "40.714 -74.006"
    }
}